Monoclonal antibody-based therapy

Current Opinion in Oncology

Volumn 8, Issue 6, 1996, Pages 493-498

  Von Mehren, Margaret ^a   Weiner, Louis M ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CANCER GROWTH FACTOR; CARBOXYPEPTIDASE A; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOTOXIN; INTERLEUKIN 6 ANTIBODY; IODINE 131; LIPOSOME; METHOTREXATE; MONOCLONAL ANTIBODY; PRODRUG; PSEUDOMONAS EXOTOXIN; STAPHYLOCOCCUS ENTEROTOXIN A; SUPERANTIGEN; TUMOR ANTIGEN; VASOACTIVE AGENT; YTTRIUM 90;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; EFFECTOR CELL; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; LIVER METASTASIS; MULTIPLE MYELOMA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0029949679     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199611000-00009     Document Type: Article

References (34)

1. Khazaeli MB, Conry RM, LoBuglio AF: Human Immune response to monoclonal antibodies. J Immunother 1994, 15:42-52.
2. Jain RK, Baxter LT: Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 1988, 48:7022-7032.
3. Badger CC, Anasetti C, Davis J, Bernstein ID: Treatment of malignancy with unmodified antibody. Pathol Immunopathol Res 1987, 6:419-434.
4. Holland G, Zlotnik A: Interleukin-10 and cancer. Cancer Invest 1993, 11:751-758.
5. Nergaard P, Hougaard S, Poulsen HS, Spang-Thomsen M: Transforming growth factor β and cancer. Cancer Treat Rev 1995, 21:367-403.
6. Fanger MW, Morganelli PM, Guyre PM: Bispecific antibodies. Crit Rev Immunol 1992, 12:101-124.
7. Porter RR: Separation of fractions of rabbit gamma-globulin contain-ing the antibody and antigenic combining sites. Nature 1958, 182:670-671.
8. Nisonoff A, Wissler FC, Lipman LN: Properties of the major component of a peptic digest of rabbit antibody. Science 1960, 132:1770-1771.
9. Dhingra K, Fritsche H, Murray JL, LoBuglio AF, Khazaeli MD, Kelley S, Tepper MA, Grasela D, Buzdar A, Valero V, Booser D, Whealin H, Collins TJ, Pursley JM, Hortobagyi G: Phase I clinical and pharmacological study of suppression of human anti mouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res 1995, 55:3060-3067. Phase I testing of a new drug that may have a role in suppressing HAMA responses to murine monoclonal antibodies.
10. HER2 monoclonal antibody In patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744. Phase II testing of a humanized monoclonal antibody demonstrating an 11.6% response rate in women with breast cancers that overexpress c-erbB-2.
11. Sands H: Radioimmunoconjugates: an overview of problems and promises. Antibod Immunoconj Radiopharma 1988, 1:213-226.
12. Epstein AL, Khawli LA, Hornick JL, Taylor CR: Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules after conjugation with Interleukin-2. Cancer Res 1995, 55:2673-2680. A novel approach for increasing tumor vasculature permeability, targeting interleukin-2 to basement membrane antigen and allowing for an increase in accumulation of a second tumor targeted antibody.
13. Huang SK, Mayhew EM, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos, D: Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992, 52:6774-6781.
14. HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci U S A 1995, 92:1327-1331. Preclinical study describing the use of liposomes that incorporate a c-erbB-2 Fab to target c-erbB-2 overexpressing cell lines; liposomes containing doxorubicin are shown to result in targeted uptake of doxorubicin.
15. 99mTc: the role of metabolism and kinetics. Cancer Res 1995, 55:5777s-5785s.
16. Benhar I, Reiter Y, Pai LH, Pastan I: Administration of disulfide stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice. Int J Cancer 1995, 62:351-355.
17. Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, Blair H-J, Wolf FG, Becker WS, Goldenberg DM: Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995, 55:3825-3834.
18. Stein R, Goldenberg DM, Thorpe SR, Basu A, Mattes MJ: Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotopes in tumors. Cancer Res 1995, 55:3132-3139.
19. 2 fragment against high- and low-EGFR-expressing carcinomas in nude mice. Int J Cancer 1995, 62:643-650.
20. Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M: Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head neck or lung cancer. Br J Cancer 1996, 73:228-235.
21. Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995, 86:685-691. Intriguing study of patients with advanced multiple myeloma treated with an antibody against a "growth factor," interleukin-6.
22. Kroesen BJ, Helfrich W, Bakker A, Wubbena AS, Bakker H, KaI HB, The TH, de Leij L: Reduction of EGP-2 positive pulmonary metastases by bispecific-antibody-redirected T cells in an immunocompetent rat model. Int J Cancer 1995, 61:812-818.
23. Mack M, Riethmüller G, Kufer P: A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995, 92:7021-7025.
24. HER2 overexpressing tumor cells. Int J Cancer 1995, 62:319-324.
25. Michon J, Moutel S, Barbet J, Romet-Lemonne J-L, Deo YM, Fridman WH, Teillaud, J-L: In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-FcγRI bispecific antibody. Blood 1995, 86:1124-1130.
26. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M, Wardwell K, Guyre, V, Morley, TL, Arvizu, C, Fanger, MW: Phase la/lb trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol 1995, 13:2281-2292. Human trial utilizing a bispecific antibody targeting c-erbB-2 and an Fc receptor found on monocytes.
27. Weiner LM, Clark JI, Davey M, Li WS, de Palazzo IG, Ring DB, Alpaugh RK: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and FcγRIII. Cancer Res 1995, 55:4586-4593. Human trial utilizing a bispecific antibody targeting c-erbB-2 and Fc receptor found on macrophages, polymorphonuclear leukocytes, and natural killer cells.
28. Gralow J, Weiner L, Ring D, Clark J, Alpaugh K, Disis M, Cheever M: HER-2/neu specific immunity can be induced by therapy with 2B1, a bispecific monoclonal antibody binding to HER-2/neu and CD16. Proc Am Soc Clin Oncol 1995, 14:A1807. Demonstration of an adaptive immune response to internal portions of c-erbB-2 in patients treated with 2B1.
29. Lando PA, Dohlsten M, Ohlsson L, Kalland T: Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Int J Cancer 1995, 62:466-471.
30. Giantonio BJ, Weiner LM, Alpaugh RK, McAleer C, Bonjo C, Schultz JF, Shannon BT, Vitek L, Dohlsten M, Kalland T, Persson B: Superantigen based immunotherapy: a phase I trial of the staphylococcal enterotoxin A immunoconjugate LS4565 in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1996, 15:A1379. Clinical trial utilizing staphylococcal enterotoxin A targeted to an antigen expressed on colorectal and pancreatic cancers; preclinical studies of this agent described in Lando et al. (Int J Cancer 1995, 62:466-471).
31. Deonarain MP, Epenetos AA: Targeting enzymes for cancer therapy: old enzymes in new roles. Br J Cancer 1994, 70:786-794.
32. Vitols KS, Haag-Zeino B, Baer T, Montejano YD, Huennekens FM: Methotrexate-α-phenylalanine: optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate. Cancer Res 1995, 55:478-481. Preclinical studies describing the use of a tumor-specific antibody conjugated to carboxypeptidase A to activate a methotrexate prodrug at the tumor site.
33. Marasco WA: Intracellular antibodies (intrabodies) as research agents and therapeutic molecules for gene therapy. Immunotechnology 1995, 1:1-19. An excellent review of intrabodies.
34. Deshane J, Cabrera G, Grim JE, Siegal GP, Pike J, Alvarez RD, Curiel DT: Targeted eradication of ovarian cancer mediated by intracellular expression of anti-erbB-2 single chain antibody. Intriguing new approach targeting a gene that codes for an antibody fragment that binds c-erbB-2; in vitro demonstration of downregulation of c-erbB-2 expression and loss of a transforming phenotype.